Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robyn T Sussman

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Frontiers in Oncology|March 27, 2020
CAMKV Is a Candidate Immunotherapeutic Target in <i>MYCN</i> Amplified NeuroblastomaRobyn T Sussman, Jo Lynne Rokita, Kevin Huang, et al.
The Journal of Molecular Diagnostics : JMD|December 12, 2022
Rapid and Automated Semiconductor-Based Next-Generation Sequencing for Simultaneous Detection of Somatic DNA and RNA Aberrations in Myeloid NeoplasmsChristopher M Sande, Rui Wu, Guang Yang, et al.
Scientific Data|April 15, 2020
Epigenomic profiling of neuroblastoma cell linesKristen Upton, Apexa Modi, Khushbu Patel, et al.
Cancer Genetics|December 17, 2018
Validation of a next-generation sequencing oncology panel optimized for low input DNARobyn T Sussman, Sydney Shaffer, Elizabeth M Azzato, et al.
Molecular and Cellular Biology|October 12, 2011
Inhibition of the single downstream target BAG1 activates the latent apoptotic potential of MYCXiao-Yong Zhang, Harla K Pfeiffer, Hestia S Mellert, et al.
Cancer Research|November 8, 2013
USP22 regulates oncogenic signaling pathways to drive lethal cancer progressionRandy S Schrecengost, Jeffry L Dean, Jonathan F Goodwin, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 2, 2023
ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult PatientsDavid M Meredith, Linda D Cooley, Adrian Dubuc, et al.
Cancer Cell|September 13, 2017
Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk NeuroblastomaKristopher R Bosse, Pichai Raman, Zhongyu Zhu, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Frontiers in Oncology|March 27, 2020
CAMKV Is a Candidate Immunotherapeutic Target in <i>MYCN</i> Amplified NeuroblastomaRobyn T Sussman, Jo Lynne Rokita, Kevin Huang, et al.
The Journal of Molecular Diagnostics : JMD|December 12, 2022
Rapid and Automated Semiconductor-Based Next-Generation Sequencing for Simultaneous Detection of Somatic DNA and RNA Aberrations in Myeloid NeoplasmsChristopher M Sande, Rui Wu, Guang Yang, et al.
Scientific Data|April 15, 2020
Epigenomic profiling of neuroblastoma cell linesKristen Upton, Apexa Modi, Khushbu Patel, et al.
Cancer Genetics|December 17, 2018
Validation of a next-generation sequencing oncology panel optimized for low input DNARobyn T Sussman, Sydney Shaffer, Elizabeth M Azzato, et al.
Molecular and Cellular Biology|October 12, 2011
Inhibition of the single downstream target BAG1 activates the latent apoptotic potential of MYCXiao-Yong Zhang, Harla K Pfeiffer, Hestia S Mellert, et al.
Cancer Research|November 8, 2013
USP22 regulates oncogenic signaling pathways to drive lethal cancer progressionRandy S Schrecengost, Jeffry L Dean, Jonathan F Goodwin, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 2, 2023
ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult PatientsDavid M Meredith, Linda D Cooley, Adrian Dubuc, et al.
Cancer Cell|September 13, 2017
Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk NeuroblastomaKristopher R Bosse, Pichai Raman, Zhongyu Zhu, et al.
Pageof 2